SOURCE: INSYS Therapeutics
PHOENIX, AZ--(Marketwired - Mar 19, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the 13th Annual Needham Healthcare Conference on April 8 - 9, 2014 at the Westin Grand Central in New York City.
Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial, will host the presentation on Tuesday, April 8, 2014 at 4:20 p.m. EDT.
During this presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of this presentation during the event, please visit: www.insysrx.com. A replay of this webcast will be available for 30 days after the initial presentation.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.